A collaboration between Gilead Sciences and Dragonfly Therapeutics was announced May 2, with an end goal of bringing Dragonfly’s DF7001 natural killer (NK) engager program designed for patients with cancer or inflammatory diseases to fruition. 

Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.

Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies which the immunotherapy company’s chairman and CEO believes is one-of-a-kind.

Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.

Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.

Shares of Cellectis Therapeutics were up in trading after the gene-editing pioneer company forged a deal with Cambridge, Mass.-based Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.

Neoleukin was benched by the FDA with a clinical hold for the biopharma company’s lead cancer immunotherapy candidate.  

Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.

Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.

Gilead Sciences, Kite, and oNKo-innate announced that the companies entered into a three-year cancer immunotherapy research collaboration to support the discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.